DeepMed Research

RTOG Foundation, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.rtog.org

Clinical Trials

Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment

Phase 2

Not yet recruiting

Conditions: Intracranial Meningioma

Interventions: Drug: [177Lu]Lu-DOTATATE
Other: Standard of Care treatments

First Posted Date: 2025-05-02

Last Posted Date: 2025-05-06

Lead Sponsor: RTOG Foundation, Inc.

Target Recruit Count: 153

Registration Number: NCT06955169

A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Radiation: Radiation Therapy
Drug: Bicalutamide
Drug: Enzalutamide
Drug: GnRH analog

First Posted Date: 2019-01-18

Last Posted Date: 2024-10-16

Lead Sponsor: RTOG Foundation, Inc.

Target Recruit Count: 188

Registration Number: NCT03809000

Locations: 🇺🇸
USC Medical Center - Los Angeles County, Los Angeles, California, United States
🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸
Sutter Roseville Medical Center, Roseville, California, United States

and more 105 locations

Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma

Phase 3

Completed

Conditions: Glioblastoma Multiforme
Glioma
Astrocytoma

Interventions: Radiation: Hyperfractionated RT
Radiation: Conventional RT
Drug: Carmustine

First Posted Date: 2018-10-26

Last Posted Date: 2019-11-12

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 712

Registration Number: NCT03722355

SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma

Phase 2

Recruiting

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)

Interventions: Drug: Pembrolizumab
Radiation: Stereotactic Body Radiation Therapy (SBRT)

First Posted Date: 2018-06-06

Last Posted Date: 2025-04-22

Lead Sponsor: RTOG Foundation, Inc.

Target Recruit Count: 102

Registration Number: NCT03546582

Locations: 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸
University of Arizona Cancer Center - North Campus, Tucson, Arizona, United States
🇺🇸
Ohio State University, Columbus, Ohio, United States

and more 18 locations

Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC

Phase 3

Terminated

Conditions: Non-Small Cell Lung Cancer

Interventions: Radiation: Radiation Therapy (RT)
Drug: Cisplatin
Drug: Etoposide
Other: Placebo
Drug: Nivolumab

First Posted Date: 2016-05-11

Last Posted Date: 2021-06-02

Lead Sponsor: RTOG Foundation, Inc.

Target Recruit Count: 20

Registration Number: NCT02768558

Locations: 🇺🇸
Virginia Mason, Seattle, Washington, United States
🇺🇸
Mount Sinai Cancer Research Center, Miami Beach, Florida, United States
🇺🇸
Reading Hospital/McGlinn Cancer Institute, West Reading, Pennsylvania, United States

and more 13 locations

Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer

Phase 1

Completed

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)

Interventions: Drug: Nivolumab
Drug: Cisplatin
Drug: Cetuximab
Radiation: IMRT

First Posted Date: 2016-05-06

Last Posted Date: 2022-11-29

Lead Sponsor: RTOG Foundation, Inc.

Target Recruit Count: 40

Registration Number: NCT02764593

Locations: 🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
UPMC - Shadyside Hospital, Pittsburgh, Pennsylvania, United States

and more 8 locations

Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma

Phase 2

Terminated

Conditions: Glioblastoma
Glioma
Gliosarcoma

Interventions: Drug: Bevacizumab
Device: TTFields Therapy

First Posted Date: 2016-04-19

Last Posted Date: 2021-06-02

Lead Sponsor: RTOG Foundation, Inc.

Target Recruit Count: 3

Registration Number: NCT02743078

Locations: 🇺🇸
University of California Irvine, Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

and more 8 locations

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

Phase 3

Active, not recruiting

Conditions: Stage II Non-Small Cell Lung Cancer AJCC v7
Stage IIA Non-Small Cell Lung Carcinoma AJCC v7
Stage IIB Non-Small Cell Lung Carcinoma AJCC v7
Stage III Non-Small Cell Lung Cancer AJCC v7
Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Stage IIIB Non-Small Cell Lung Cancer AJCC v7

Interventions: Drug: Carboplatin
Drug: Cisplatin
Biological: Durvalumab
Drug: Etoposide
Drug: Paclitaxel
Drug: Pemetrexed Disodium
Radiation: Photon Beam Radiation Therapy
Radiation: Proton Beam Radiation Therapy
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2013-11-25

Last Posted Date: 2024-12-18

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 330

Registration Number: NCT01993810

Locations: 🇺🇸
MD Anderson Regional Care Center-Sugar Land, Sugar Land, Texas, United States
🇺🇸
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

and more 27 locations

Radiation Therapy and Cisplatin With or Without Surgery in Treating Patients With Stage III-IV Oropharyngeal Cancer

Phase 2

Withdrawn

Conditions: Tongue Cancer
Stage IVA Squamous Cell Carcinoma of the Oropharynx
Stage III Squamous Cell Carcinoma of the Oropharynx

Interventions: Procedure: therapeutic conventional surgery
Radiation: intensity-modulated radiation therapy
Drug: cisplatin
Procedure: quality-of-life assessment
Other: laboratory biomarker analysis

First Posted Date: 2013-10-01

Last Posted Date: 2015-03-20

Lead Sponsor: Radiation Therapy Oncology Group

Registration Number: NCT01953952

Locations: 🇺🇸
Stanford University Hospitals and Clinics, Stanford, California, United States

High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

Phase 2

Terminated

Conditions: Pancreatic Adenocarcinoma
Stage III Pancreatic Cancer

Interventions: Radiation: low intensity radiation therapy
Drug: Capecitabine
Drug: nab-Paclitaxel
Drug: Gemcitabine
Radiation: high intensity radiation therapy

First Posted Date: 2013-08-13

Last Posted Date: 2018-07-13

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 20

Registration Number: NCT01921751

Locations: 🇺🇸
Radiation Oncology Associates PC, Fort Wayne, Indiana, United States
🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States

and more 43 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy